Rapid alterations in protein expression are commonly regulated by adjusting translation. In addition to cap-dependent translation, which is e.g. induced by pro-proliferative signaling via the mammalian target of rapamycin (mTOR)-kinase, alternative modes of translation, such as internal ribosome entry site (IRES)-dependent translation, are often enhanced under stress conditions, even if cap-dependent translation is attenuated. Common stress stimuli comprise nutrient deprivation, hypoxia, but also inflammatory signals supplied by infiltrating immune cells. Yet, the impact of inflammatory microenvironments on translation in tumor cells still remains largely elusive. In the present study, we aimed at identifying translationally deregulated targets in tumor cells under inflammatory conditions. Using polysome profiling and microarray analysis, we identified cyp24a1 (1,25-dihydroxyvitamin D3 24-hydroxylase) to be translationally upregulated in breast tumor cells co-cultured with conditioned medium of activated monocyte-derived macrophages (CM). Using bicistronic reporter assays, we identified and validated an IRES within the 5′ untranslated region (5′UTR) of cyp24a1, which enhances translation of cyp24a1 upon CM treatment. Furthermore, IRES-dependent translation of cyp24a1 by CM was sensitive to phosphatidyl-inositol-3-kinase (PI3K) inhibition, while constitutive activation of Akt sufficed to induce its IRES activity. Our data provide evidence that cyp24a1 expression is translationally regulated via an IRES element, which is responsive to an inflammatory environment. Considering the negative feedback impact of cyp24a1 on the vitamin D responses, the identification of a novel, translational mechanism of cyp24a1 regulation might open new possibilities to overcome the current limitations of vitamin D as tumor therapeutic option.
References
[1]
Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10: 254–266.
[2]
Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136: 731–745.
[3]
Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9–22.
[4]
Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, et al. (1994) Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371: 762–767.
[5]
Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initiation and cancer. Oncogene 25: 6416–6422.
[6]
Averous J, Fonseca BD, Proud CG (2008) Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27: 1106–1113.
[7]
Blagden SP, Willis AE (2011) The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol 8: 280–291.
[8]
Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671–688.
[9]
Holcik M (2004) Targeting translation for treatment of cancer–a novel role for IRES? Curr Cancer Drug Targets 4: 299–311.
[10]
Spriggs KA, Stoneley M, Bushell M, Willis AE (2008) Re-programming of translation following cell stress allows IRES-mediated translation to predominate. Biol Cell 100: 27–38.
[11]
Lang KJ, Kappel A, Goodall GJ (2002) Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 13: 1792–1801.
[12]
Lewis SM, Holcik M (2005) IRES in distress: translational regulation of the inhibitor of apoptosis proteins XIAP and HIAP2 during cell stress. Cell Death Differ 12: 547–553.
[13]
Sherrill KW, Byrd MP, Van Eden ME, Lloyd RE (2004) BCL-2 translation is mediated via internal ribosome entry during cell stress. J Biol Chem 279: 29066–29074.
[14]
Spriggs KA, Mitchell SA, Willis AE (2005) Investigation of interactions of polypyrimidine tract-binding protein with artificial internal ribosome entry segments. Biochem Soc Trans 33: 1483–1486.
[15]
Dhamija S, Kuehne N, Winzen R, Doerrie A, Dittrich-Breiholz O, et al. (2011) Interleukin-1 Activates Synthesis of Interleukin-6 by Interfering with a KH-type Splicing Regulatory Protein (KSRP)-dependent Translational Silencing Mechanism. J Biol Chem 286: 33279–33288.
[16]
Rübsamen D, Blees JS, Schulz K, Doring C, Hansmann ML, et al. (2012) IRES-dependent translation of egr2 is induced under inflammatory conditions. RNA 18: 1910–1920.
[17]
Schmid T, Jansen AP, Baker AR, Hegamyer G, Hagan JP, et al. (2008) Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res 68: 1254–1260.
[18]
Coldwell MJ, Mitchell SA, Stoneley M, MacFarlane M, Willis AE (2000) Initiation of Apaf-1 translation by internal ribosome entry. Oncogene 19: 899–905.
[19]
Schmid T, Bajer MM, Blees JS, Eifler LK, Milke L, et al. (2011) Inflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation. Carcinogenesis 32: 1427–1433.
[20]
Yasuda M, Schmid T, Rübsamen D, Colburn NH, Irie K, et al. (2010) Downregulation of programmed cell death 4 by inflammatory conditions contributes to the generation of the tumor promoting microenvironment. Mol Carcinog 49: 837–848.
[21]
Gruber AR, Lorenz R, Bernhart SH, Neubock R, Hofacker IL (2008) The Vienna RNA websuite. Nucleic Acids Res 36: W70–74.
[22]
van der Velden AW, Thomas AA (1999) The role of the 5′ untranslated region of an mRNA in translation regulation during development. Int J Biochem Cell Biol 31: 87–106.
[23]
Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, et al. (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485: 109–113.
[24]
Van Eden ME, Byrd MP, Sherrill KW, Lloyd RE (2004) Demonstrating internal ribosome entry sites in eukaryotic mRNAs using stringent RNA test procedures. RNA 10: 720–730.
[25]
Chen KS, DeLuca HF (1995) Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1263: 1–9.
[26]
Horvath E, Lakatos P, Balla B, Kosa JP, Tobias B, et al. (2012) Marked increase of CYP24A1 mRNA level in hepatocellular carcinoma cell lines following vitamin D administration. Anticancer Res 32: 4791–4796.
[27]
Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, et al. (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 115: 177–186.
[28]
Moreau A, Maurel P, Vilarem MJ, Pascussi JM (2007) Constitutive androstane receptor-vitamin D receptor crosstalk: consequence on CYP24 gene expression. Biochem Biophys Res Commun 360: 76–82.
[29]
Konno Y, Kodama S, Moore R, Kamiya N, Negishi M (2009) Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation. Mol Pharmacol 75: 265–271.
[30]
Novakovic B, Sibson M, Ng HK, Manuelpillai U, Rakyan V, et al. (2009) Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem 284: 14838–14848.
[31]
Svitkin YV, Herdy B, Costa-Mattioli M, Gingras AC, Raught B, et al. (2005) Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol 25: 10556–10565.
[32]
Kobayashi N, Saeki K, Yuo A (2003) Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce cell cycle progression through the synthesis of c-Myc protein by internal ribosome entry site-mediated translation via phosphatidylinositol 3-kinase pathway in human factor-dependent leukemic cells. Blood 102: 3186–3195.
[33]
Petz M, Them NC, Huber H, Mikulits W (2012) PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition. Nucleic Acids Res 40: 9738–9749.
[34]
Schuster I (2011) Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 1814: 186–199.
[35]
Hobaus J, Hummel DM, Thiem U, Fetahu IS, Aggarwal A, et al. (2013) Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer. Int J Cancer.
[36]
Lopes N, Sousa B, Martins D, Gomes M, Vieira D, et al. (2010) Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10: 483.
[37]
Balla B, Kosa JP, Tobias B, Halaszlaki C, Takacs I, et al. (2011) Marked increase in CYP24A1 gene expression in human papillary thyroid cancer. Thyroid 21: 459–460.
[38]
Horvath HC, Lakatos P, Kosa JP, Bacsi K, Borka K, et al. (2010) The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 58: 277–285.
